Literature DB >> 9736336

The association between CD20 and Src-family Tyrosine kinases requires an additional factor.

I J Popoff1, J A Savage, J Blake, P Johnson, J P Deans.   

Abstract

CD20 is a B cell surface protein which can initiate intracellular signals involving tyrosine kinase activation, and modify B cell growth and differentiation. CD20 is tightly associated with the Src-family kinases Lyn, Fyn and Lck; however, the mechanism of interaction remains to be determined. Association between CD20 and Src-family kinases has been detected in peripheral blood B cells and in 5 out of 8 unrelated B cell lines. The lack of CD20-associated kinase activity in some cell lines offered an opportunity to investigate the mechanism of CD20 associations. All 8 B cell lines were found to express Lyn, and, with one exception, all cell lines also expressed Fyn. Lck, however, was not detected in any of the cell lines in which CD20 failed to coprecipitate kinase activity. To test the possibility that Lck was required for assembly of the CD20 complex, Lck was transfected into one of the 3 CD20/kinase association-deficient lines, namely T51. CD20 did not coprecipitate kinase activity from the transfected T51 cells, despite their expression of high levels of exogenous Lck, as well as endogenous Lyn and Fyn. CD20 cDNA from T51 was sequenced and found to be normal. These data establish that association between CD20 and Src-family kinases requires an additional factor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736336     DOI: 10.1016/s0161-5890(98)00042-x

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

Review 1.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 2.  Clinical consequences of defects in B-cell development.

Authors:  Andre M Vale; Harry W Schroeder
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

Review 3.  Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms.

Authors:  Wasif Riaz; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

4.  Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation.

Authors:  Min Fengling; Liu Fenju; Wen Wanxin; Zhai Lijia; Tong Jiandong; Wang Zu; Yuan Xin; Gao Qingxiang
Journal:  Radiat Environ Biophys       Date:  2009-08-04       Impact factor: 1.925

5.  Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression.

Authors:  Lina Song; Wei Zhang; Hong Chen; Xizhi Zhang; Haoan Wu; Ming Ma; Zhongqiu Wang; Ning Gu; Yu Zhang
Journal:  Int J Nanomedicine       Date:  2019-02-01

6.  Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells.

Authors:  George W Small; Howard L McLeod; Kristy L Richards
Journal:  PeerJ       Date:  2013-02-12       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.